XBRANE Xbrane Biopharma AB (publ)
14.20SEK+13.60%Mkt Cap: 27.99M $P/E: —1d ago
Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. It offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including…
Industry Peers
Biotechnology$127.24BUSDP/E 29.3
$76.05BUSDP/E 18.3
$74.84BUSD
$56.77BUSDP/E 37.1
$58.21BUSDP/E 35.5
$41.93BUSDP/E 17.9
$42.84BUSD
$41.27BUSDP/E 64.9
$32.61BUSDP/E 30.0
$29.97BUSDP/E 37.8
$25.66BUSD
$24.05BUSD
$23.24BUSDP/E 29.8
$22.98BUSD
$22.23BUSDP/E 30.6
$22.85BUSDP/E 14.4
$15.02BUSDP/E 15.9
$14.87BUSDP/E 17.3
$14.45BUSDP/E 18.4
$13.81BUSD
| Headline | Source | Time |
|---|---|---|
Older | ||
Xbrane Biopharma AB (STU:7XB0) Q2 2026 Earnings Call Highlights: Navigating Challenges and ... Xbrane Biopharma AB (STU:7XB0) reports a mixed quarter with strategic advancements in Europe and the US, despite financial hurdles and competitive pressures. | ||
Xbrane Biopharma AB (STU:7XB0) Q2 2026 Earnings Call Highlights: Strategic Moves and Financial ... Xbrane Biopharma AB (STU:7XB0) outlines cost reduction plans and pipeline progress amid competitive pressures and financial hurdles. | ||
FFastighetsvärlden | ||